Noveris Health Sciences Inc. (FRA:0NF1)
Germany · Delayed Price · Currency is EUR | Market Cap | 81.44M +19,745.1% |
| Revenue (ttm) | n/a |
| Net Income | 1.40M |
| EPS | 1.13 |
| Shares Out | n/a |
| PE Ratio | 58.24 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,529 |
| Average Volume | 707 |
| Open | 1.240 |
| Previous Close | 0.785 |
| Day's Range | 1.170 - 1.290 |
| 52-Week Range | 0.050 - 1.290 |
| Beta | n/a |
| RSI | 83.95 |
| Earnings Date | Mar 31, 2026 |
About Noveris Health Sciences
Noveris Health Sciences Inc., a biotechnology company, engages in the research, development, and commercialization of psilocybin products to treat mental health conditions. The company primarily focuses on treating nicotine addiction and post-traumatic stress disorder. It also develops MYCO-005, MYCO-006, and MYCO-007 for MDMA and psilocybin analogs. The company has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds. Noveris Health Sciences... [Read more]
News
Noveris Provides Announces Trading Halt Order, And Clarification As To Article
Vancouver, British Columbia, March 26, 2026 – TheNewswire – Noveris Health Sciences Inc. (the “ Company ”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) announces that the British Columbia Securities Commissio...
Noveris Announces Closing of Life Offering
Vancouver, British Columbia – TheNewswire - March 18, 2026 – Noveris Health Sciences Inc. (the “ Company ”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) is pleased to announce that it has completed its previo...
Noveris Health Sciences Inc. Unaware Of Any Material Change
Vancouver, British Columbia, March 16, 2026 – TheNewswire - At the request of CIRO, Noveris Health Sciences Inc. (the “ Company ”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) wishes to confirm that the Compa...
Noveris Health Sciences Launches Investor Website and Engages Fairfax Partners Inc. for Investor Relations and Digital Marketing Services
VANCOUVER, BC – TheNewswire - March 13, 202 6 – Noveris Health Sciences Inc. ( CSE: NVRS) ( FSE: 0NF0) ( OTC: MYCOF) (the " Company ") is pleased to announce the launch of its new investor-facing w...
Noveris Announces Resignation Of CEO
Vancouver, British Columbia, March 10, 2026 – TheNewswire — Noveris Health Sciences Inc. (the “ Company ”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) announces today that Joshua Bartch has resigned as direc...
Noveris Announces Conversion Of Debentures; Filing Of Early Warning Reports By JJK Holdings Ltd. And Joshua Bartch
Vancouver, British Columbia, March 6, 2026 — TheNewswire - Noveris Health Sciences Inc. (the “ Company ”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) announces today the conversion of debentures in the aggre...
JJK Holdings Ltd. Acquires $7,878,792 Convertible Debenture Of Noveris Health Sciences Inc.; Filing Of Early Warning Reports By JJK Holdings Ltd.
Vancouver, British Columbia, February 27, 2026 - TheNewswire — Noveris Health Sciences Inc. (the “ Company ”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) announces today that JJK Holdings Ltd. (“ JJK ”) acqu...
Noveris Provides Supplemental Disclosure Regarding Previously Announced Convertible Debenture Issuances
Vancouver, British Columbia, February 18, 2026 — TheNewswire - Noveris Health Sciences Inc. (the “ Company ”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) announces that it is providing additional disclosure ...
CSE Bulletin: Name and Symbol Change - Mydecine Innovations Group Inc. (MYCO)
Toronto, Ontario--(Newsfile Corp. - Le 2 février/February 2026) - Mydecine Innovations Group Inc. (MYCO) has announced a name and symbol change to Noveris Health Sciences Inc. (NVRS). Shares will begi...
CSE Bulletin: Consolidation - Mydecine Innovations Group Inc. (MYCO)
Toronto, Ontario--(Newsfile Corp. - Le 20 octobre/October 2025) - Mydecine Innovations Group Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post...
Mydecine Innovations Group Closes Debt Settlements
Vancouver, British Columbia, October 14, 2025 — TheNewswire - Mydecine Innovations Group Inc. (the “Company”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) is pleased to announce that it has closed the previou...
Mydecine Innovations Group Announces Results Of Shareholder Meeting And Provides Corporate Update
Vancouver, British Columbia, October 6, 2025 — TheNewswire - Mydecine Innovations Group Inc. (the “Company”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) is pleased to announce the results of voting at its an...
Mydecine Innovations Group Provides Update On Annual Financial Statements
Vancouver, British Columbia, June 26, 2025 — TheNewswire - Mydecine Innovations Group Inc. (the “ Company ”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) is providing this update on the status of a management...
Mydecine Innovations Group Provides Update on Annual Financial Statements
Vancouver, British Columbia – TheNewswire - June 12, 2025 — Mydecine Innovations Group Inc. (the “ Company ”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) is providing this update on the status of a managemen...
Mydecine Innovations Group Announces Late Filing Of Annual Financial Statements And Management Cease Trade Order
Vancouver, British Columbia, May 01, 2025 — TheNewswire - Mydecine Innovations Group Inc. (the “Company”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) announces today that as a result of delays to its audit, ...
Mydecine Innovations Group Announces Changes To Board And Management
Vancouver, British Columbia, March 26, 2025 — TheNewswire - Mydecine Innovations Group Inc. (the “ Company ”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) is pleased to announce the appointments of Mr. Peter ...
Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds
VANCOUVER, British Columbia, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NF0), a leading biotechnology comp...
Mydecine Innovations Group Announces Director Resignation
VANCOUVER, British Columbia, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE: 0NF0), a forefront biotechnology c...
Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound
VANCOUVER, British Columbia, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA), a forefront biotechnology co...
Mydecine Announces Update Regarding the Special Access Program
DENVER, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovativ...
Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreements
VANCOUVER, British Columbia, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engin...
Mydecine Provides Q4 2023 Business Update
VANCOUVER, British Columbia, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engi...
Mydecine Innovations Group Announces Listing on the Canadian Securities Exchange and Delisting from the NEO
VANCOUVER, British Columbia, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NF0) a biotechnology company engineering the n...
Mydecine Innovations Group Announces Expected U.K. Dual Listing Admission Date
VANCOUVER, British Columbia, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the ...
Mydecine Innovations Announces Amended Press Release Relating to the Closing of Prospectus Supplement Financing
VANCOUVER, British Columbia, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the...